Traders Purchase High Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw some unusual options trading activity on Wednesday. Investors acquired 25,745 call options on the stock. This represents an increase of 295% compared to the typical volume of 6,521 call options.

Analyst Upgrades and Downgrades

RVPH has been the subject of several recent analyst reports. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. HC Wainwright lowered their target price on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Benchmark decreased their price target on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. Finally, D. Boral Capital reissued a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.86.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals in the 2nd quarter worth $31,000. Lido Advisors LLC acquired a new position in Reviva Pharmaceuticals during the third quarter worth $37,000. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares in the last quarter. Finally, Persistent Asset Partners Ltd grew its position in shares of Reviva Pharmaceuticals by 300.0% in the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Trading Down 45.5%

Shares of NASDAQ RVPH opened at $0.32 on Wednesday. The company has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.52. The stock has a market cap of $36.97 million, a price-to-earnings ratio of -0.70 and a beta of -0.02. Reviva Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $2.17.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. Analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.